Discordance between core needle biopsy (CNB) and excisional biopsy (EB) for estrogen receptor (ER), progesterone receptor (PgR) and HER2 status in early breast cancer (EBC)

Annals of Oncology

Volumn 20, Issue 12, 2009, Pages 1948-1952

  Arnedos, Monica ^a   Nerurkar, A ^a   Osin, P ^a   A'Hern, R ^b   Smith, I E ^a   Dowsett, M ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Core needle biopsy; Early breast cancer; Estrogen receptor; HER2; Progesterone receptor

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ARTICLE; BREAST BIOPSY; BREAST CANCER; CANCER GRADING; CONTROLLED STUDY; DIAGNOSTIC VALUE; EARLY CANCER; FLUORESCENCE IN SITU HYBRIDIZATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MASTECTOMY; NEEDLE BIOPSY; PARTIAL MASTECTOMY; PREDICTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; UNITED KINGDOM;

EID: 70849114499     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp234     Document Type: Article

References (30)

1. American Cancer Society. Information and Resources for Cancer: Breast, Colon, Prostate, lung 2008. http://www.cancer.org/docroot/CRI/content/ CRI_2_2_1X_How_many_people_get_breast_cancer_5.asp?rnav=cri.
2. Pettine S, Place R, Babu S et al. Stereotactic breast biopsy is accurate, minimally invasive, and cost effective. Am J Surg 1996; 171: 474-476.
3. Pijnappel RM, van Dalen A, Borel Rinkes IH et al. The diagnostic accuracy of core biopsy in palpable and non-palpable breast lesions. Eur J Radiol 1997; 24: 120-123.
4. Verkooijen HM, Peeters PH, Buskens E et al. Diagnostic accuracy of large-core needle biopsy for nonpalpable breast disease: A meta-analysis. Br J Cancer 2000; 82: 1017-1021.
5. Dillon MF, Hill AD, Quinn CM et al. The accuracy of ultrasound, stereotactic, and clinical core biopsies in the diagnosis of breast cancer, with an analysis of false-negative cases. Ann Surg 2005; 242: 701-707.
6. Neubauer H, Gall C, Vogel U et al. Changes in tumour biological markers during primary systemic chemotherapy (PST). Anticancer Res 2008; 28: 1797-1804.
7. Goldhirsch A, Wood WC, Gelber RD et al. Meeting highlights: Updated international expert consensus on the primary therapy of early breast cancer. J Clin Oncol 2003; 21: 3357-3365.
8. Slamon DJ, Clark GM, Wong SG et al. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177-182.
9. Konecny G, Pauletti G, Pegram M et al. Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. J Natl Cancer Inst 2003; 95: 142-153.
10. Menard S, Valagussa P, Pilotti S et al. Response to cyclophosphamide, methotrexate, and fluorouracil in lymph node-positive breast cancer according to HER2 overexpression and other tumor biologic variables. J Clin Oncol 2001; 19: 329-335.
11. Usami S, Moriya T, Amari M et al. Reliability of prognostic factors in breast carcinoma determined by core needle biopsy. Jpn J Clin Oncol 2007; 37: 250-255.
12. Cahill RA, Walsh D, Landers RJ, Watson RG. Preoperative profiling of symptomatic breast cancer by diagnostic core biopsy. Ann Surg Oncol 2006; 13: 45-51.
13. Burge CN, Chang HR, Apple SK. Do the histologic features and results of breast cancer biomarker studies differ between core biopsy and surgical excision specimens? Breast 2006; 15: 167-172.
14. Mann GB, Fahey VD, Feleppa F, Buchanan MR. Reliance on hormone receptor assays of surgical specimens may compromise outcome in patients with breast cancer. J Clin Oncol 2005; 23: 5148-5154.
15. Cavaliere A, Sidoni A, Scheibel M et al. Biopathologic profile of breast cancer core biopsy: Is it always a valid method? Cancer Lett 2005; 218: 117-121.
16. Badoual C, Maruani A, Ghorra C et al. Pathological prognostic factors of invasive breast carcinoma in ultrasound-guided large core biopsies - correlation with subsequent surgical excisions. Breast 2005; 14: 22-27.
17. Al Sarakbi W, Salhab M, Thomas V, Mokbel K. Is preoperative core biopsy accurate in determining the hormone receptor status in women with invasive breast cancer? Int Semin Surg Oncol 2005; 2: 15.
18. Harris K, Morafa I, Thomas V, Mokbel K. Core biopsy is accurate in determining the hormone receptor status of early breast cancer. Am J Surg 2004; 187: 568. author reply 568.
19. Gotzinger P, Gebhard B, Gnant M et al. Value of punch biopsy in diagnosis of palpable breast tumors. A prospective analysis of 150 patients. Chirurg 1998; 69: 1068-1071.
20. Hodi Z, Chakrabarti J, Lee AH et al. The reliability of assessment of oestrogen receptor expression on needle core biopsy specimens of invasive carcinomas of the breast. J Clin Pathol 2007; 60: 299-302.
21. Taucher S, Rudas M, Mader RM et al. Prognostic markers in breast cancer: the reliability of HER2/neu status in core needle biopsy of 325 patients with primary breast cancer. Wien Klin Wochenschr 2004; 116: 26-31.
22. Mueller-Holzner E, Fink V, Frede T, Marth C. Immunohistochemical determination of HER2 expression in breast cancer from core biopsy specimens: A reliable predictor of HER2 status of the whole tumor. Breast Cancer Res Treat 2001; 69: 13-19.
23. Eradat J, Rao N, Shintaku I et al. A Comparison of Immunohistochemistry (IHC) and Fluoresence In situ Hybridization (FISH) Testing in the Determination of Her-2/neu Expression in Core Needle Biopsy (CNB) and Excisional Biopsies (EB) in Breast Cancer. Proceedings San Antonio Breast Cancer Symposium 2006 (Abstr 6002).
24. Allred DC, Harvey JM, Berardo M, Clark GM. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 1998; 11: 155-168.
25. Wolff AC, Hammond ME, Schwartz JN et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007; 25: 118-145.
26. Zidan A, Christie Brown JS, Peston D, Shousha S. Oestrogen and progesterone receptor assessment in core biopsy specimens of breast carcinoma. J Clin Pathol 1997; 50: 27-29.
27. Quinn E, Salter J, Hills M et al. Concordance between tissue microarray and whole tissue sections for ER expression and PgR and HER-2 Status: A pilot study for the Trans-ATAC trial. Eur J Cancer Suppl 2008; 6: 140 (Abstr 311).
28. Yamashita H, Yando Y, Nishio M et al. Immunohistochemical evaluation of hormone receptor status for predicting response to endocrine therapy in metastatic breast cancer. Breast Cancer 2006; 13: 74-83.
29. Dowsett M, Allred C, Knox J et al. Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the arimidex, tamoxifen, alone or in combination trial. J Clin Oncol 2008; 26: 1059-1065.
30. Fisher B, Dignam J, Bryant J, Wolmark N. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: Updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J Natl Cancer Inst 2001; 93: 684-690.